Skip to content
Sign in

Company

Armata Pharmaceuticals

Open structure map

Description

Headquarters
US

Structure of Armata Pharmaceuticals

Armata Pharmaceuticals

Company

2 connections
OwnershipInvestment and holdings
OwnProducts and technology
Relationship began2026
Armata PharmaceuticalsCompany · 2 connections
Layer 1

OwnershipInvestment and holdings1

OwnProducts and technology1

Place in the network

No. 65907 of 118934top 56%down 8262 places this week

2 direct links

In a group of 451 closely linked entities, around

Weighted by public relations with evidence, recomputed daily.

Relations

Money between companies

Who invests in, owns, acquires or finances whom, from the relations AiSeek holds with evidence.

PentagonfinancesArmata Pharmace…

Into Armata Pharmaceuticals

Lines show that a relation exists and which way it points; their thickness carries no amount. Dots only move to show the direction.

Arrows show the direction of the relationship. Filter to focus on a business area.

  • Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-11-13 05:05
      using its proprietary bacteriophage-based technology.
      View source
    • CompanyPR Newswire news releases2026-10-07 19:00
      using its proprietary bacteriophage-based technology
      View source
  • Pentagonfinances →Armata Pharmaceuticals
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-11-13 05:05
      Received $3.7 million in additional non-dilutive funding from the DoW[i]
      View source
    • CompanyPR Newswire news releases2026-11-13 05:05
      We also appreciate the continued financial support of the U.S. Department of War ("DoW")
      View source
  • Armata Pharmaceuticalsproduces →AP-SA02
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-11-13 05:05
      Production of clinical trial material for the planned Phase 3 study is underway, with one cGMP production run and vialing of AP-SA02 drug product completed in the third quarter of 2026.
      View source

Showing 1 to 3 of 3

Claims

Read the assertion alongside its sources. Expand a row to inspect the evidence.

FactEvidence 1
net cash used in operating activities for nine months ended september 30 2026-19,964 thousands

**Net cash used in operating activities** | | | (19,964)

PR Newswire news releases · 2026-11-13 05:05

View evidence
  • CompanyPR Newswire news releases2026-11-13 05:05
    **Net cash used in operating activities** | | | (19,964)
    View source
FactEvidence 1
net income loss for nine months ended september 30 202613,652 thousands

Net income (loss) | | $ | 13,652

PR Newswire news releases · 2026-11-13 05:05

View evidence
  • CompanyPR Newswire news releases2026-11-13 05:05
    Net income (loss) | | $ | 13,652
    View source
FactEvidence 1
cash cash equivalents and restricted cash end of period at september 30 202622,437 thousands

Cash, cash equivalents and restricted cash, end of period | | $ | 22,437

PR Newswire news releases · 2026-11-13 05:05

View evidence
  • CompanyPR Newswire news releases2026-11-13 05:05
    Cash, cash equivalents and restricted cash, end of period | | $ | 22,437
    View source
FactEvidence 1
total operating expenses for the three months ended september 30 202610,554 thousands

Total operating expenses | | 10,554

PR Newswire news releases · 2026-11-13 05:05

View evidence
  • CompanyPR Newswire news releases2026-11-13 05:05
    Total operating expenses | | 10,554
    View source
FactEvidence 1
grant and award revenue for the three months ended september 30 20263,171 thousands

**Grant and award revenue** | $ | 3,171

PR Newswire news releases · 2026-11-13 05:05

View evidence
  • CompanyPR Newswire news releases2026-11-13 05:05
    **Grant and award revenue** | $ | 3,171
    View source
FactEvidence 1
research and development expenses for the three months ended september 30 20266,830 thousands

Research and development | | 6,830

PR Newswire news releases · 2026-11-13 05:05

View evidence
  • CompanyPR Newswire news releases2026-11-13 05:05
    Research and development | | 6,830
    View source

Showing 1 to 6 of 21

Market and valuation

Valuation data is available on Pro and Research.

Included in Pro

Suggest a page to watch

Know a page of this company that matters, such as pricing, a changelog, terms or careers? Suggest it. We read every suggestion; a page we add is watched for everyone, and we only count a change when two looks in a row agree.

Sign in to suggest a page

Not available: Company signals · Financials · Filings · Sites · Guidance